VRTX — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-05

• We are a global biotechnology company that invests in scientific innovation to create transformative medicines for

• people with serious diseases, with a focus on specialty markets. We have seven approved medicines: five that treat the

• underlying cause of cystic fibrosis (“CF”), a life-threatening genetic disease, one that treats severe sickle cell disease

• (“SCD”) and transfusion dependent beta thalassemia (“TDT”), life shortening inherited blood disorders, and one that treats

• moderate-to-severe acute pain. We are also preparing for the anticipated launch of povetacicept, a potential treatment for IgA

Text removed vs the prior filing · source: 10-Q · 2025-11-04

• We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. We have seven approved medicines: five that treat the underlying cause of cystic fibrosis (“CF”), a life-threatening gen…

• In December 2024, the U.S. Food and Drug Administration (the “FDA”) approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), our once-daily next-in-class triple combination for the treatment of people with CF 6 years of age and older, and our fifth CF medicine. ALYFTREK is also approved in the Unit…

• CASGEVY (exagamglogene autotemcel), our ex-vivo, non-viral CRISPR/Cas9 gene-edited cell therapy, is approved in the U.S., the E.U., the U.K., the Kingdom of Saudi Arabia (“Saudi Arabia”), the Kingdom of Bahrain (“Bahrain”), Qatar, the United Arab Emirates (the “UAE”), Switzerland and Canada for the …

• In January 2025, the FDA approved JOURNAVX, our selective non-opioid NaV1.8 pain signal inhibitor, for the treatment of people with moderate-to-severe acute pain. We have begun our commercial launch of JOURNAVX in the U.S. for eligible adults.

• In the third quarter of 2025, our net product revenues increased to $3.1 billion as compared to $2.8 billion in the third quarter of 2024, primarily due to continued strong patient demand for TRIKAFTA/KAFTRIO and early contributions from three ongoing launches.

Text added vs the prior filing · source: 10-Q · 2026-05-05

• Information required by this item is incorporated by reference from the discussion in Part II, Item 7A, “Quantitative and

• Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year ended December 31, 2025,

Text removed vs the prior filing · source: 10-Q · 2025-11-04

• Information required by this item is incorporated by reference from the discussion in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on February 13, 2025.

Text added vs the prior filing · source: 10-Q · 2026-05-05

• Our management (under the supervision and with the participation of our chief executive officer and chief financial

• officer), after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and

• 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly

• Report on Form 10-Q, has concluded that, based on such evaluation, as of March 31, 2026 our disclosure controls and

• procedures were effective and designed to provide reasonable assurance that the information required to be disclosed is

Text removed vs the prior filing · source: 10-Q · 2025-11-04

• Our management (under the supervision and with the participation of our chief executive officer and chief financial officer), after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amende…

• No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) occurred during the three months ended September 30, 2025 that has materially affected, or is reasonably likely to materially affect, our int…

Text added vs the prior filing · source: 10-Q · 2026-05-05

• statements, we are not currently subject to any material legal proceedings.

Text added vs the prior filing · source: 10-Q · 2026-05-05

• Our policy governing transactions in our securities by our directors, officers, and employees permits our officers,

• directors and employees to enter into trading plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934,

• as amended (each a “Trading Plan”). In the first quarter of 2026, none of our directors or officers adopted or terminated a

Text removed vs the prior filing · source: 10-Q · 2025-11-04

• Our policy governing transactions in our securities by our directors, officers, and employees permits our officers, directors and employees to enter into trading plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The following table describes the written plans fo…

• Name and TitleDate of Adoption of Trading PlanScheduled Expiration Date of Trading Plan (1)Maximum Shares Subject to Trading Plan

• EVP, Global Medicines Development and Medical Affairs, Chief Medical Officer

• EVP, Chief Technical Operations Officer, Head of Biopharmaceuitcal Sciences and Manufacturing Operations

• (1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.